Advertisement
U.S. markets close in 3 hours 16 minutes
  • S&P 500

    5,251.68
    +3.19 (+0.06%)
     
  • Dow 30

    39,766.15
    +6.07 (+0.02%)
     
  • Nasdaq

    16,385.78
    -13.74 (-0.08%)
     
  • Russell 2000

    2,133.43
    +19.09 (+0.90%)
     
  • Crude Oil

    82.76
    +1.41 (+1.73%)
     
  • Gold

    2,241.70
    +29.00 (+1.31%)
     
  • Silver

    24.97
    +0.21 (+0.86%)
     
  • EUR/USD

    1.0807
    -0.0022 (-0.21%)
     
  • 10-Yr Bond

    4.1910
    -0.0050 (-0.12%)
     
  • GBP/USD

    1.2644
    +0.0006 (+0.05%)
     
  • USD/JPY

    151.2560
    +0.0100 (+0.01%)
     
  • Bitcoin USD

    70,889.06
    +1,752.84 (+2.54%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,960.85
    +28.87 (+0.36%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Teva in talks to buy Allergan big generic-drug unit: WSJ

Teva Pharmaceutical Industries' Jerusalem oral solid dosage plant (OSD) is seen December 21, 2011. REUTERS/Ronen Zvulun

(Reuters) - Israeli drug maker Teva Pharmaceutical Industries Ltd (TEVA.TA) is in talks to combine with Allergan Plc's (AGN.N) big generic-drug business, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

A deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday, one of the people said, according to the Journal. The Allergan unit would be spun off and combined with Teva, which has a market value of $60 billion, this person told the newspaper.

(Reporting by Eric Beech in Washington; Editing by Bernard Or)

Advertisement